NASDAQ: KZIA
Kazia Therapeutics Ltd Stock Forecast, Predictions & Price Target

Analyst price target for KZIA

Based on 2 analysts offering 12 month price targets for Kazia Therapeutics Ltd

Min Forecast
$13.00+20.37%
Avg Forecast
$14.00+29.63%
Max Forecast
$15.00+38.89%

Should I buy or sell KZIA stock?

Based on 2 analysts offering ratings for Kazia Therapeutics Ltd.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KZIA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates KZIA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their KZIA stock forecasts and price targets.

KZIA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-10
lockedlocked$00.00+00.00%2025-06-11

1 of 1

Forecast return on equity

Is KZIA forecast to generate an efficient return?

Company
0%
Industry
167.47%
Market
90.43%
KZIA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KZIA forecast to generate an efficient return on assets?

Company
0%
Industry
44.43%
KZIA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KZIA earnings per share forecast

What is KZIA's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.01
Avg 2 year Forecast
$0.00
Avg 3 year Forecast
$0.00

KZIA revenue forecast

What is KZIA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$60.0k-96.14%
Avg 2 year Forecast
$40.0k-97.43%
Avg 3 year Forecast
$1.3M-17.68%
KZIA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KZIA revenue growth forecast

How is KZIA forecast to perform vs Biotechnology companies and vs the US market?

Company
-13.01%
Industry
57.08%
Market
10.39%
KZIA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KZIA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KZIA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KZIA$10.80$14.00+29.63%Strong Buy
CDIO$4.15N/AN/A
RNAZ$8.69$280.00+3,123.95%Buy
IBO$0.59N/AN/A
PMCB$1.08N/AN/A

Kazia Therapeutics Stock Forecast FAQ

Is Kazia Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: KZIA) stock is to Strong Buy KZIA stock.

Out of 2 analysts, 1 (50%) are recommending KZIA as a Strong Buy, 1 (50%) are recommending KZIA as a Buy, 0 (0%) are recommending KZIA as a Hold, 0 (0%) are recommending KZIA as a Sell, and 0 (0%) are recommending KZIA as a Strong Sell.

If you're new to stock investing, here's how to buy Kazia Therapeutics stock.

What is KZIA's earnings growth forecast for 2026-2029?

(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.

Kazia Therapeutics's earnings in 2025 is -$18,446,946.On average, 1 Wall Street analyst forecast KZIA's earnings for 2026 to be -$665,702, with the lowest KZIA earnings forecast at -$665,702, and the highest KZIA earnings forecast at -$665,702. On average, 1 Wall Street analyst forecast KZIA's earnings for 2028 to be $0, with the lowest KZIA earnings forecast at $0, and the highest KZIA earnings forecast at $0.

In 2029, KZIA is forecast to generate $0 in earnings, with the lowest earnings forecast at $0 and the highest earnings forecast at $0.

What is KZIA's revenue growth forecast for 2026-2028?

(NASDAQ: KZIA) Kazia Therapeutics's forecast annual revenue growth rate of -13.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.

Kazia Therapeutics's revenue in 2025 is $1,625,509.On average, 1 Wall Street analysts forecast KZIA's revenue for 2026 to be $3,994,209, with the lowest KZIA revenue forecast at $3,994,209, and the highest KZIA revenue forecast at $3,994,209. On average, 1 Wall Street analysts forecast KZIA's revenue for 2027 to be $2,662,806, with the lowest KZIA revenue forecast at $2,662,806, and the highest KZIA revenue forecast at $2,662,806.

In 2028, KZIA is forecast to generate $85,209,801 in revenue, with the lowest revenue forecast at $85,209,801 and the highest revenue forecast at $85,209,801.

What is KZIA's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: KZIA) forecast ROA is 0%, which is lower than the forecast US Biotechnology industry average of 44.43%.

What is KZIA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year KZIA price target, the average KZIA price target is $14.00, with the highest KZIA stock price forecast at $15.00 and the lowest KZIA stock price forecast at $13.00.

On average, Wall Street analysts predict that Kazia Therapeutics's share price could reach $14.00 by Jul 10, 2026. The average Kazia Therapeutics stock price prediction forecasts a potential upside of 29.63% from the current KZIA share price of $10.80.

What is KZIA's Earnings Per Share (EPS) forecast for 2026-2029?

(NASDAQ: KZIA) Kazia Therapeutics's current Earnings Per Share (EPS) is -$22.64. On average, analysts forecast that KZIA's EPS will be -$0.01 for 2026, with the lowest EPS forecast at -$0.01, and the highest EPS forecast at -$0.01. On average, analysts forecast that KZIA's EPS will be $0.00 for 2028, with the lowest EPS forecast at $0.00, and the highest EPS forecast at $0.00. In 2029, KZIA's EPS is forecast to hit $0.00 (min: $0.00, max: $0.00).

What is KZIA's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: KZIA) forecast ROE is 0%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.